Business Context and Reporting Period
This Form 8-K, dated January 5, 2013, reports a material definitive agreement entered into by Astro-Med, Inc. (the "Company") and its wholly-owned subsidiary, Grass Technologies Corporation ("Grass"), with Natus Medical Incorporated ("Natus"). The filing details the sale of the Grass Technologies Product Group, a business unit specializing in neurodiagnostic and monitoring products including polysomnography (PSG) and electroencephalography (EEG) systems.
Key Financial Metrics and Transaction Terms
- Purchase Price: $18.6 million in cash, subject to working capital adjustments.
- Assets Acquired: Working capital (minimum $2.0 million), engineering/sales/support workforce, intellectual property, and related assets.
- Escrow: $1.8 million of the purchase price held for 12 months for indemnity purposes.
- Historical Revenue: The Business generated approximately $18.5 million in sales for the year ended January 31, 2012.
- Retained Assets: The Company retains its Grass manufacturing facility in Rockland, Massachusetts.
Material Changes and Transaction Structure
The Company is divesting a significant product group that historically contributed $18.5 million in annual sales. The transaction involves a Transition Services Agreement where the Company will continue to manufacture Grass products for Natus post-closing until Natus acquires remaining inventory. The Company is bound by a three-year non-compete covenant and a non-solicitation provision regarding the Business. The transaction is expected to close on January 31, 2013, and does not require shareholder approval.
Outlook, Risks, and Contingencies
The completion of the transaction is contingent upon customary conditions, including the accuracy of representations and warranties and compliance with obligations under the Purchase Agreement. The filing does not provide specific forward-looking guidance on the Company's overall financial outlook post-transaction, nor does it detail specific risks beyond standard transaction closing conditions. The filing text does not provide a clear value for the Company's total revenue, profit, or cash flow outside of the specific Business unit being sold.
Key Facts for Investor Verification
- Verify the exact closing date of January 31, 2013, and the final adjusted purchase price based on working capital.
- Confirm the duration and financial terms of the Transition Services Agreement for manufacturing.
- Assess the impact of the $18.5 million revenue loss on the Company's consolidated financial statements for the 2013 fiscal year.
- Review the Company's strategy for the retained Rockland, Massachusetts manufacturing facility.